前进或倒退:从2012年至2022年FDA批准的小分子药物中吸取的教训
Mingxiao Gu1,2, Sudan Sun1,2, Qidong You1,2
1State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Molecules (Basel, Switzerland)
|December 23, 2023
概括
药物开发分析揭示了FDA对小分子的第一级 (FIC) 批准的趋势. 这项研究提供了对分子性质的洞察,并预测了未来新分子实体 (NME) 的发展.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 制药科学 制药科学
背景情况:
- 药物开发在设计和识别方面面临着历史性的挑战.
- 对食品和药物管理局 (FDA) 批准的新分子实体 (NME) 的分析对于未来药物开发的见解至关重要.
研究的目的:
- 从2012-2022年分析FDA批准的NME,重点是第一类 (FIC) 小分子.
- 为了比较所有NME批准与FIC批准的趋势.
- 在治疗领域调查FIC小分子分子分子量趋势.
主要方法:
- 对FDA批准数据 (2012-2022) 的比较分析.
- 计算FIC小分子的年平均分子量趋势.
- 将数据整合到综合数据库中 (说明,SMILES,结构,研发,分子量,CLogP,使用途径).
主要成果:
- 建立了11年来小分子药物批准的全面数据库.
- 视觉化FIC小分子批准的趋势及其分子量变化.
- 确定了批准的NME的关键物理特性和发展特征.
结论:
- 该研究提供了药物化学家对FIC小分子开发的观点.
- 分析了11年的批准数据,可以预测未来的NME批准趋势.
- 了解历史趋势有助于战略药物开发规划.
相关概念视频
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Administration and Therapy Phases: Overview
475
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
475
Structure-Activity Relationships and Drug Design
727
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
727
Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K


